Semax vs PT-141: ACTH Analog vs Melanocortin Peptide Comparison | Peptpedia

Semax is derived from the ACTH(4-7) sequence (His-Phe-Arg-Trp)—the minimal core of ACTH required for receptor binding—with the stabilizing Pro-Gly-Pro extension added to increase CNS penetration and metabolic stability. Its primary mechanism is stimulation of BDNF and NGF synthesis in hippocampal and prefrontal cortical neurons through ACTH receptor interactions, with downstream effects on synaptic plasticity, neurogenesis, and neuroprotection. It has minimal classical melanocortin receptor agonism.

PT-141 is a cyclic analog of alpha-MSH (also derived from POMC), engineered to maximize MC3R and MC4R binding while minimizing MC1R activation (tanning) and hypertensive effects that limited Melanotan II's development. Its primary action is on hypothalamic and limbic MC4R to activate sexual arousal circuits through a CNS mechanism completely distinct from peripheral vasodilatory drugs like PDE5 inhibitors.

Semax is a stabilized ACTH(4-7) analog that upregulates brain-derived neurotrophic factor (BDNF) and its receptor trkB in hippocampal and cortical neurons (PMID 16996037). This neurotrophic signaling cascade promotes synaptic plasticity, long-term potentiation, and neuronal survival. Semax also modulates dopaminergic and serotonergic neurotransmitter systems, contributing to its cognitive-enhancing and antidepressant-like effects observed in preclinical and Russian clinical studies. Administration is intranasal, exploiting the olfactory nerve pathway for direct CNS delivery while bypassing first-pass hepatic metabolism.

PT-141 (Bremelanotide) is a cyclic melanocortin analog that activates MC3R and MC4R in the hypothalamus and medial preoptic area to promote sexual arousal through central dopaminergic cascades. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act peripherally on vascular smooth muscle, PT-141 generates desire and arousal through CNS circuits — a fundamentally different pharmacological approach to sexual dysfunction. Administration is subcutaneous via auto-injector, with peak plasma concentration reached approximately 1 hour post-injection.

These peptides have no overlapping therapeutic indication. Semax targets cognitive function and neuroprotection through neurotrophic factor signaling — BDNF-mediated dendritic growth, synaptic strengthening, and neuronal survival in hippocampal and prefrontal circuits. PT-141 targets sexual desire through melanocortin-mediated hypothalamic circuits — MC4R activation in the medial preoptic area drives dopamine release in mesolimbic pathways that generate subjective arousal and motivation.

The only structural connection is that both peptides are derived from endogenous neuropeptide fragments processed from the pro-opiomelanocortin (POMC) precursor: ACTH for Semax, alpha-MSH for PT-141. Both fragments originate from the same prohormone but are cleaved by different enzymes in different tissues and activate distinct receptor populations. Their downstream signaling cascades, target neural circuits, and physiological outcomes are entirely non-overlapping — making this comparison primarily educational rather than a guide for choosing between alternatives.

Semax is a registered medicine in Russia with clinical data on cognitive enhancement, stroke recovery (reducing infarct volume and improving functional outcomes in ischemic stroke patients), and attention deficit conditions. It has decades of clinical use in Russian medical practice and a well-characterized safety profile at therapeutic intranasal doses. PT-141 is FDA-approved (marketed as Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the Phase 3 RECONNECT trials involving over 1,200 women that demonstrated statistically significant increases in desire and reductions in distress compared to placebo (PMID 31599840).

Both peptides have achieved regulatory validation in their respective domains — a distinction that separates them from most research peptides. This comparison is primarily educational: researchers would not choose between Semax and PT-141 for the same indication. Semax addresses cognitive performance and neuroprotection; PT-141 addresses central sexual desire dysfunction. Their shared POMC heritage is a matter of biochemical ancestry rather than functional equivalence.